Sangamo Therapeutics, Inc. (SGMO) News
Filter SGMO News Items
SGMO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SGMO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest SGMO News From Around the Web
Below are the latest news stories about SANGAMO THERAPEUTICS INC that investors may wish to consider to help them evaluate SGMO as an investment opportunity.
Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a look at where Sangamo Therapeutics Inc. (NASDAQ:SGMO) stands against the other small-cap stocks. Fifteen small-cap stocks—predominantly under the technology sector—are taking center stage this year, boasting triple- to quadruple-digit performance in their […] |
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & MorePFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study. |
Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment PartnershipThe biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator. |
Top Midday DeclinersSangamo Therapeutics (SGMO) shares plunged 55%, a day after the company said its partner, Pfizer (PF |
Sangamo Therapeutics Stock Slumps After Pfizer Terminates Hemophilia A Gene Therapy PartnershipSangamo Therapeutics' (SGMO) shares were sinking intraday Tuesday after the company said its partner |
Top Midday Stories: Sangamo Shares Fall After Pfizer Exits Collaboration; Dave Denies DOJ AllegationsThe Dow Jones Industrial Average and the S&P 500 were basically flat, while the Nasdaq Composite was |
Pfizer Exit Sends Sangamo Plummeting 50%, Casting Doubt on Hemophilia Gene Therapy's FutureSangamo faces steep drop after Pfizer ends partnership, raising concerns about its hemophilia therapy's future |
Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug PactSangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement. |
SGMO Pre-Market Shares Drop 40% Over Pfizer (PFE) Deal CollapseInvestors continued to sell off shares in Sangamo Therapeutics Inc. (NASDAQ:SGMO) before market open on Tuesday following announcements that pharmaceutical giant Pfizer Inc. (NYSE:PFE) terminated their hemophilia A gene therapy co-development agreement. As of 8:53 am on Tuesday, shares of the company declined anew by 50.85 percent to $1.08 each. The previous day’s trading also […] |
Sangamo stock plummets 50% after Pfizer ends gene therapy dealSangamo Therapeutics Inc. (SGMO) shares plunged in Tuesday's pre-market trading by over 50% after Pfizer Inc. (PFE) terminated its partnership with the company. The two were collaborating on a gene therapy program to co-develop a treatment for hemophilia A. Sangamo is exploring "all options" to continue the program. Morning Brief co-hosts Madison Mills and Seana Smith break down the details. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Angel Smith |